<- Go Home

Bionano Genomics, Inc.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. It also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic data from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, the company offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Market Cap

$11.2M

Volume

80.2K

Cash and Equivalents

$3.6M

EBITDA

-$45.3M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$494.0K

Profit Margin

1.74%

52 Week High

$72.60

52 Week Low

$2.68

Dividend

N/A

Price / Book Value

0.24

Price / Earnings

-0.08

Price / Tangible Book Value

0.29

Enterprise Value

$11.4M

Enterprise Value / EBITDA

-0.27

Operating Income

-$58.7M

Return on Equity

127.82%

Return on Assets

-31.04

Cash and Short Term Investments

$18.2M

Debt

$18.4M

Equity

$48.2M

Revenue

$28.5M

Unlevered FCF

$1.8M

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches